403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 16, 2007 at 10:57 AM

Debate on biotech drug generics lies ahead

The House of Representatives voted last week to strengthen the U.S. Food and Drug Administration’s rule over drug companies, but the fate of biotech drug generics is yet to be written, according to this Wall Street Journal story.

The House bill must be reconciled with a measure recently passed by the Senate, opening the way to follow-on biologics, as identical copies of biotech drugs are known. Biotech companies — including many local firms — dread their coming.

The current Senate bill would allow the FDA to waive clinical trials for generic versions of already approved drugs, something that could eliminate most of the incentive to develop costly therapies and pose a safety risk, opponents say. Supporters say generics could lower health care costs and increase access to life-saving medicines.

“A compromise version of the two measures is expected to be completed in the next few months,” the Journal story says.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx